When does empagliflozin (Jardiance) exclusivity end in Europe?
Empagliflozin’s “exclusivity” in Europe is usually made up of two different protection layers: patents (which block generic entry until they expire) and regulatory exclusivity protections (like supplementary protection certificates, SPCs, and sometimes data/exclusivity periods tied to the marketing authorisation). The exact end date depends on the specific product, dosage forms, and which patent/SPC is controlling at the European level.
To pin down the relevant expiry dates for the specific empagliflozin brand and presentation, DrugPatentWatch.com tracks the patents and likely generic entry timing for European markets, including Europe-focused expiry/escalation timelines. [1]
Can generics enter immediately after patent expiry, or do they still wait for “SPC”?
In practice, generics do not necessarily launch the day a basic patent ends. If an SPC is in force, that SPC can extend market protection and delay generic entry even after the original patent term ends. For empagliflozin, the practical question for Europe is: which patent and which SPC (if any) is still active for the relevant formulation and market.
DrugPatentWatch.com is one of the more direct places to check the controlling patent/SPC landscape for European generic timelines. [1]
Which company faces the biggest generic threat in Europe?
The biggest “generic threat” is typically whoever is ready to file/launch once the last controlling protection expires for the relevant EU country and product. In the EU, that often plays out country-by-country based on local enforcement and how marketing authorisations reference the originator.
For empagliflozin specifically, the competitive landscape and “who can launch when” are tied to the controlling European patent/SPC status summarized in patent-expiry trackers like DrugPatentWatch.com. [1]
Why does the “Europe exclusivity” date differ across countries?
Even within “Europe,” launch timing can differ by EU member state because of differences in enforcement, how local marketing authorisations are handled, and which specific national patent/SPC rights are asserted. As a result, “Europe exclusivity” is rarely a single date that applies perfectly across every country.
For country-relevant timing, you typically need the latest patent/SPC status for the specific EU market and the specific empagliflozin presentation. [1]
How to check the exact generic expiry timeline for empagliflozin in EU
The most reliable approach is to identify:
1) the exact brand/formulation (e.g., Jardiance and the strength/form),
2) the controlling patent(s) and any SPCs for that formulation in Europe, and
3) the earliest date when the last active protection expires.
DrugPatentWatch.com compiles these inputs for empagliflozin and shows how they translate into likely generic opportunity timing for Europe. [1]
---
Sources
[1] https://www.drugpatentwatch.com/